Development of a standardised tool to survey MDR-/XDR-TB case management in Europe

European Respiratory Journal

Volumn 36, Issue 1, 2010, Pages 208-211

  Sotgiu, G ^a   Centis, R ^b   D'Ambrosio, L ^b   De Lorenzo, S ^c   D'Arcy Richardson, M ^d   Lange, C ^e   Manissero, D ^f   Migliori, G B ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCCS   (Italy)

^c Morelli Hospital   (Italy)

^d PATH   (United States)

^e RESEARCH CENTER BORSTEL   (Germany)

^f EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CASE MANAGEMENT; DIAGNOSTIC TEST; DRUG MONITORING; EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INFECTION CONTROL; LETTER; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SELF EVALUATION; STANDARDIZATION; VALIDATION PROCESS; HEALTH CARE SURVEY; STANDARDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; EUROPE; HEALTH CARE SURVEYS; HUMANS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77954629686     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00186409     Document Type: Letter

References (13)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva, World Health Organization, 2008.
2. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
3. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
4. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
5. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007; 13: 780-782.
6. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
7. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
8. Migliori GB, Richardson MD, Lange C. Of blind men and elephants: making sense of extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178: 1000-1001.
9. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430-432.
10. Migliori GB, Sotgiu G, Jaramillo E, et al. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool. Int J Tuberc Lung Dis 2009; 13: 1305-1308.
11. Migliori GB, Hopewell PC, Blasi F, et al. Improving the TB case management: the International Standards for Tuberculosis Care. Eur Respir J 2006; 28: 687-690. (Pubitemid 46331987)
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis WHO/HTM/TB/2008.402. Geneva, WHO, 2008.
13. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.